Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Iain Martin

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Bioorganic & Medicinal Chemistry Letters|February 13, 2010
Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitorsZoran Rankovic, Jiaqiang Cai, Jennifer Kerr, et al.
Bioorganic & Medicinal Chemistry Letters|July 6, 2010
6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitorsJiaqiang Cai, Mark Baugh, Darcey Black, et al.
Bioorganic & Medicinal Chemistry Letters|September 17, 2010
Optimisation of 2-cyano-pyrimidine inhibitors of cathepsin K: improving selectivity over hERGZoran Rankovic, Jiaqiang Cai, Jennifer Kerr, et al.
Cancer Discovery|November 2, 2023
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from HyperinsulinemiaAndreas Varkaris, Ermira Pazolli, Hakan Gunaydin, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Bioorganic & Medicinal Chemistry Letters|February 13, 2010
Design and optimization of a series of novel 2-cyano-pyrimidines as cathepsin K inhibitorsZoran Rankovic, Jiaqiang Cai, Jennifer Kerr, et al.
Bioorganic & Medicinal Chemistry Letters|July 6, 2010
6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitorsJiaqiang Cai, Mark Baugh, Darcey Black, et al.
Bioorganic & Medicinal Chemistry Letters|September 17, 2010
Optimisation of 2-cyano-pyrimidine inhibitors of cathepsin K: improving selectivity over hERGZoran Rankovic, Jiaqiang Cai, Jennifer Kerr, et al.
Cancer Discovery|November 2, 2023
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from HyperinsulinemiaAndreas Varkaris, Ermira Pazolli, Hakan Gunaydin, et al.
Pageof 5